Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov 4:10:1300.
doi: 10.3389/fphar.2019.01300. eCollection 2019.

Antitumor Activity and Treatment-Related Toxicity Associated With Nivolumab Plus Ipilimumab in Advanced Malignancies: A Systematic Review and Meta-Analysis

Hang Xu  1 , Ping Tan  1 , Jianzhong Ai  1 , Shiyu Zhang  1 , Xiaonan Zheng  2 , Xinyang Liao  1 , Lu Yang  1 , Qiang Wei  1
Affiliations

Antitumor Activity and Treatment-Related Toxicity Associated With Nivolumab Plus Ipilimumab in Advanced Malignancies: A Systematic Review and Meta-Analysis

Hang Xu et al. Front Pharmacol. .

Abstract

Combining immune checkpoint inhibitors has shown its efficacy compared to monotherapy in advanced malignancies. We conducted this meta-analysis to provide latest evidence on the objective response rate (ORR) and incidence of treatment-related high-grade adverse events (AEs) during nivolumab and ipilimumab combination treatment and further explore from different drug dose level. PubMed and the 2019 American Society of Clinical Oncology (ASCO) annual meeting abstracts were searched for qualified clinical trials up to June 2019. Of the 23 clinical trials (13 from publications and 11 from ASCO abstracts) included, 2,114 and 2,674 patients were eligible for efficacy and safety analysis, respectively. Pooled analysis suggested that the overall ORR was achieved in 34.5% [95% confidence interval (CI), 29.1-40.4%] of patients. There was no significant difference between nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks (N3I1-Q3W) and nivolumab 1 mg/kg plus ipilimumab 3 mg/kg every 3 weeks (N1I3-Q3W) arms in ORR [30.8% vs 41%; odds ratio (OR), 0.72; 95% CI, 0.39-1.30; P = 0.275]. Grade 3-4 AEs related to combination therapy occurred in 39.9% (95% CI, 33.5-46.7%) of patients; the most commonly reported grade 3-4 treatment-related AEs were diarrhea (5.28%), colitis (3.96%) and increased alanine aminotransferase (3.51%). Incidence of grade 3-4 AEs were significant lower in N3I1-Q3W arm than in N1I3-Q3W arm (31.3% vs 55.9%; OR 0.52; 95% CI, 0.32-0.87; P = 0.012). Treatment-related death was rare and occurred in 2.0% (95% CI, 1.5-2.7%) of patients. Our comprehensive study provides more precise data on the incidence of treatment-related high-grade AEs and ORR among patients receiving nivolumab and ipilimumab combination regimens. Patients on the N3I1-Q3W arm had comparable ORR and significantly occurred less grade 3-4 AEs than patients on the N1I3-Q3W arm. Our finding is of great importance in assisting clinical trial design and clinical medication choice.

Keywords: adverse events; combination; dosage; ipilimumab; nivolumab; objective response rate.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow diagram of the eligible trials included in this study. ASCO, American Society of Clinical Oncology; QoL, quality of life.
Figure 2
Figure 2
Forest plots of the objective response rate associated with nivolumab and ipilimumab combination treatment. ORR, Objective response rate; N, nivolumab; I, ipilimumab; CI, Confidence interval.
Figure 3
Figure 3
Forest plots of the incidence of grade 3–4 adverse events associated with nivolumab and ipilimumab combination treatment. CI, Confidence interval.
Figure 4
Figure 4
Incidence of fatal adverse events associated with nivolumab and ipilimumab combination treatment. Abstr, Abstract; CI, Confidence interval.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Antonia S., Goldberg S. B., Balmanoukian A., Chaft J. E., Sanborn R. E., Gupta A., et al. (2016. a). Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 17 (3), 299–308. 10.1016/s1470-2045(15)00544-6 - DOI - PMC - PubMed
    1. Antonia S. J., Lopez-Martin J. A., Bendell J., Ott P. A., Taylor M., Eder J. P., et al. (2016. b). Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 17 (7), 883–895. 10.1016/s1470-2045(16)30098-5 - DOI - PubMed
    1. Bazhenova L., Redman M. W., Gettinger S. N., Hirsch F. R., Mack P. C., Schwartz L. H., et al. (2019). A phase III randomized study of nivolumab plus ipilimumab versus nivolumab for previously treated patients with stage IV squamous cell lung cancer and no matching biomarker (Lung-MAP Sub-Study S1400I, NCT02785952). J. Clin. Oncol. 37 (15_suppl), 9014–9014. 10.1200/JCO.2019.37.15_suppl.9014 - DOI
    1. Buchbinder E. I., Desai A. (2016). CTLA-4 and PD-1 Pathways: similarities, differences, and implications of their inhibition. Am. J. Clin. Oncol. 39 (1), 98–106. 10.1097/coc.0000000000000239 - DOI - PMC - PubMed
    1. Calabro L., Morra A., Giannarelli D., Amato G., D’Incecco A., Covre A., et al. (2018). Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. Lancet Respir. Med. 6 (6), 451–460. 10.1016/s2213-2600(18)30151-6 - DOI - PubMed

Publication types

LinkOut - more resources